Patients with hyperglycemia can also have advanced glycation products and other metabolic abnormalities that may affect eNOS-mediated intracellular signaling pathways; even the PI3K–Akt pathway and Akt downstream to PI3K that is inhibited by ipatasertib. This evidence concerns the gene AKT1 and Hyperglycemia.